ReviewInternational urology and nephrology2016
Diabetic nephropathy: What does the future hold?
Review in International urology and nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 41 citations in OpenAlex.
- Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.Journal of the American Heart Association · 2017Trial
- The Key Role of Nutritional Intervention in Delaying Disease Progression and the Therapeutic Management of Diabetic Kidney Disease-A Challenge for Physicians and Patients.Journal of personalized medicine · 2024Review
- Article
- The nephroprotective action of Passiflora edulis in streptozotocin-induced diabetes.Scientific reports · 2022Article
- Biochemical Analysis of Urine Samples from Diabetic and Hypertensive Patients without Renal Dysfunction Using Spectrophotometry and Raman Spectroscopy Techniques Aiming Classification and Diagnosis.Bioengineering (Basel, Switzerland) · 2022Article
- Cystatin C, renal resistance index, and kidney injury molecule-1 are potential early predictors of diabetic kidney disease in children with type 1 diabetes.Frontiers in pediatrics · 2022Article
- Study of the Active Components and Molecular Mechanism ofFrontiers in molecular biosciences · 2021Article
- Correlations between Iron Metabolism Parameters, Inflammatory Markers and Lipid Profile Indicators in Patients with Type 1 and Type 2 Diabetes Mellitus.Journal of personalized medicine · 2020Article
- Clinical Trials on Diabetic Nephropathy: A Cross-Sectional Analysis.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019Article
- New Areas of Interest: Is There a Role for Omega-3 Fatty Acid Supplementation in Patients With Diabetes and Cardiovascular Disease?Current diabetes reports · 2019Review
- Evaluation of endocan and endoglin levels in chronic kidney disease due to diabetes mellitus.Archives of medical science : AMS · 2019Article
- Mathematical model of hemodynamic mechanisms and consequences of glomerular hypertension in diabetic mice.NPJ systems biology and applications · 2019Article
- Diabetic nephropathy: recent advances in pathophysiology and challenges in dietary management.Diabetology & metabolic syndrome · 2019Review
- Mesenchymal stem cells-microvesicle-miR-451a ameliorate early diabetic kidney injury by negative regulation of P15 and P19.Experimental biology and medicine (Maywood, N.J.) · 2018Article
- Defining Phenotypes in Diabetic Nephropathy: a novel approach using a cross-sectional analysis of a single centre cohort.Scientific reports · 2018Article
- Diabetic Nephropathy: a Tangled Web to Unweave.Cardiovascular drugs and therapy · 2017Review
- CXCR3 knockdown protects against high glucose-induced podocyte apoptosis and inflammatory cytokine production at the onset of diabetic nephropathy.International journal of clinical and experimental pathology · 2017Article
- Diosmin Modulates the NF-kB Signal Transduction Pathways and Downregulation of Various Oxidative Stress Markers in Alloxan-Induced Diabetic Nephropathy.Inflammation · 2016Article
- New molecular insights in diabetic nephropathy.International urology and nephrology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The consensus management of diabetic nephropathy (DN) in 2015 involves good control of glycaemia, dyslipidaemia and blood pressure (BP). Blockade of the renin-angiotensin-aldosterone system using angiotensin-converting enzyme inhibitors, angiotensin-2 receptor blockers or mineralocorticoid inhibitors are key therapeutic approaches, shown to be beneficial once overt nephropathy is manifest, as either, or both, of albuminuria and loss of glomerular filtration rate. Some significant additional clinical benefits in slowing the progression of DN was reported from the Remission clinic experience, where simultaneous intensive control of BP, tight glycaemic control, weight loss, exercise and smoking cessation were prioritised in the management of DN. This has not proved possible to translate to more conventional clinical settings. This review briefly looks over the history and limitations of current therapy from landmark papers and expert reviews, and following an extensive PubMed search identifies the most promising clinical biomarkers (both established and proposed). Many challenges need to be addressed urgently as in order to obtain novel therapies in the clinic; we also need to examine what we mean by remission, stability and progression of DN in the modern era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.